Physician profile
Colleen Digman
NPI 1760438535
$7,803.73
in general payments reported to CMS, 2019-2025
31 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $1,188 · 2021: $968 · 2022: $1,208 · 2023: $1,329 · 2024: $868 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.85 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,185.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $533.40 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.84 | 2019-2025 | Jardiance |
| Amgen INC. | $384.72 | 2019-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $340.68 | 2020-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $207.02 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $198.70 | 2019-2023 | Omnipod |
| Medtronic, INC. | $191.06 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $172.21 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $171.05 | 2019-2020 | |
| Abbvie INC. | $162.44 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $141.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $103.55 | 2023 | |
| Xeris Pharmaceuticals, INC. | $80.76 | 2021-2025 | Gvoke Hypopen |
| Ascensia Diabetes Care US INC. | $75.40 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $44.29 | 2019-2021 | |
| Radius Health, INC. | $43.81 | 2019-2025 | |
| Antares Pharma, INC. | $39.25 | 2019-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $34.19 | 2022-2023 | |
| Sequel Med Tech, LLC | $32.65 | 2025 | Twiist |
| Ipsen Biopharmaceuticals, INC | $32.61 | 2019-2021 | |
| Medtronic Minimed, INC. | $25.60 | 2019 | |
| Stryker Corporation | $18.57 | 2025 | Audion Et Dilation System |
| Corcept Therapeutics | $17.66 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $16.92 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $15.97 | 2020 | |
| Ibsa Pharma INC. | $14.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.02 | 2024 | |
| Kyowa Kirin, INC. | $12.96 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $12.42 | 2019 | |
| Pfizer INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Digman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.